Disclosed herein are synthesis and use of covalent inhibitors selective for Transcriptional Enhancer Factor TEF-1 (TEAD1), which can be used for treatment of cancers such as glioblastoma, gastric cancer, colorectal cancer, pancreatic ductal adenocarcinoma (PDAC), and malignant pleural mesothelioma (MPM). Further disclosed herein are pharmaceutical compositions including the TEAD1 inhibitor and methods of treating cancers using the same.

Substituted aromatic sulfonamides of formula (I) ##STR00001##
pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.

Substituted aromatic sulfonamides of formula (I) ##STR00001##
pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.

The application relates to a compound of Formula (I′) or (I):

##STR00001##

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I′) or (I), and a method of treating or preventing a disease in which SSAO plays a role.

The present invention relates to the use of strobilurin type compounds of formula I and the N-oxides and the salts thereof for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein (also referred to as F129L mutation in the mitochondrial cytochrome b gene) conferring resistance to Qo inhibitors, and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, and to seeds coated with at least one such compound.

The present invention relates to the use of strobilurin type compounds of formula I and the N-oxides and the salts thereof for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein (also referred to as F129L mutation in the mitochondrial cytochrome b gene) conferring resistance to Qo inhibitors, and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, and to seeds coated with at least one such compound.

Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.

Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.

A secondary battery includes a positive electrode, a negative electrode, and an electrolytic solution where (A) the electrolytic solution contains a solvent and an electrolyte salt, the solvent containing ethylene carbonate, (B) a content of the electrolyte salt is from 0.8 mol/kg to 2.0 mol/kg both inclusive, (C) a content of the ethylene carbonate in the solvent is from 10 wt % to 30 wt % both inclusive, (D) a ratio M2/M1 of a number M2 of moles of the ethylene carbonate to a number M1 of moles of the electrolyte salt is from 0.4 to 2.4 both inclusive, and (E) the electrolytic solution contains at least one of sulfone compounds.

A secondary battery includes a positive electrode, a negative electrode, and an electrolytic solution where (A) the electrolytic solution contains a solvent and an electrolyte salt, the solvent containing ethylene carbonate, (B) a content of the electrolyte salt is from 0.8 mol/kg to 2.0 mol/kg both inclusive, (C) a content of the ethylene carbonate in the solvent is from 10 wt % to 30 wt % both inclusive, (D) a ratio M2/M1 of a number M2 of moles of the ethylene carbonate to a number M1 of moles of the electrolyte salt is from 0.4 to 2.4 both inclusive, and (E) the electrolytic solution contains at least one of sulfone compounds.